植入式心律调节器市场- 按产品（单腔起搏器、双腔起搏器、双心室/CRT 起搏器）、按应用（心动过缓、心律不整）、最终用途（医院和诊所、心臟护理中心、ASC）和预测，2024 年 - 2032

预计2024 年至2032 年间，植入式心律调节器市场规模的复合年增长率将达到4.6%，原因是心血管疾病（尤其是心律不整、心臟阻塞和心房颤动）盛行率不断上升，需要使用起搏器来调节心律。据报道，心房颤动影响全球约 4,000 万人。医疗技术的不断进步促进了更复杂、更可靠的心律调节器设备的开发，包括相容于 MRI 的起搏器和无铅起搏器，以提高患者的安全性和舒适度。

增强的诊断能力和更容易获得先进的心臟护理也使得能够更早发现和治疗需要起搏器干预的心臟疾病。患者和医疗保健提供者对心臟健康的认识不断提高，以及早期干预的好处，有助于提高植入式起搏器的采用率。各国政府的措施和有利的报销政策也有助于使患者更容易获得这些救生设备。

植入式心律调节器产业分为产品、应用、最终用途和地区。

从产品来看，由于其成本效益和简单性，单腔起搏器细分市场的市场规模将在2024 年至2032 年期间产生可观的收入，使其成为对患者和医疗保健提供者都有吸引力的选择。单腔心律调节器通常更容易植入，需要更短的手术时间，同时减少併发症和住院时间的风险。它们对患有特定类型心律不整的患者特别有益，例如伴有心搏过缓的房颤，主要需要在心室的一个心室起搏。

由于心房颤动、心搏过缓和心臟传导阻滞等各种心律不整的高盛行率和不断增加的诊断，心律不整应用领域的植入式起搏器市场预计将在2024 年至2032 年出现强劲增长。这些情况会扰乱心臟的正常节律，导致疲劳、头晕和昏厥等症状，严重影响患者的生活品质。

亚太地区植入式心律调节器产业规模预计在 2024 年至 2032 年期间出现可观的成长。这是由于日本、中国和韩国等国家的人口迅速老化，导致需要起搏器干预的心血管疾病发生率更高。城市化进程的加速和生活方式的改变也将导致心臟相关疾病的增加，从而推动区域市场的成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 心血管疾病盛行率增加
    • 技术进步
    • 越来越多地转向微创手术
    • 有利的报销方案
  • 产业陷阱与挑战
    • 植入式心律调节器成本高
    • 风险和併发症
• 成长潜力分析
• 监管环境
• 技术景观
• 未来市场趋势
• 报销场景
• 波特的分析
• PESTEL分析
• 定价分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按产品分类，2021 - 2032 年

• 主要趋势
• 单腔起搏器
  • 单腔心房
  • 单腔心室
• 双腔起搏器
• 双心室/CRT起搏器

第 6 章：市场估计与预测：按应用分类，2021 - 2032

• 主要趋势
• 心搏过缓
• 心律不整
• 其他应用

第 7 章：市场估计与预测：按最终用途，2021 - 2032 年

• 主要趋势
• 医院和诊所
• 心臟护理中心
• 门诊手术中心
• 其他最终用户

第 8 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• Abbott Laboratories, Inc.
• BIOTRONIK SE & Co. KG
• Boston Scientific Corporation
• Lepu Medical Technology
• Medico S.R.L.
• Medtronic plc
• MicroPort Scientific Corporation
• Shree Pacetronix Ltd.
• Vitatron

Implantable pacemakers market size is predicted to register 4.6% CAGR between 2024 and 2032, driven by increasing prevalence of cardiovascular diseases, particularly arrhythmia's, heart blockages, and atrial fibrillation, which necessitate the use of pacemakers to regulate heart rhythms. As per reports, atrial fibrillation affects around 40 million people worldwide. Rising advancements in medical technologies have led to the development of more sophisticated and reliable pacemaker devices, including MRI-compatible pacemakers and lead less pacemakers to offer enhanced patient safety and comfort.

Enhanced diagnostic capabilities and greater accessibility to advanced cardiac care are also enabling earlier detection and treatment of heart conditions that require pacemaker intervention. Rising awareness about heart health and the benefits of early intervention among both patients and healthcare providers are contributing to higher adoption rates of implantable pacemakers. Government initiatives and favorable reimbursement policies in various countries are also helping in making these life-saving devices more accessible to patients.

The implantable pacemakers industry is segmented into product, application, end-use and region.

Based on product, the market size from the single chamber pacemakers segment will generate substantial revenue from 2024-2032 due to its cost-effectiveness and simplicity, making it an attractive option for both patients and healthcare providers. Single chamber pacemakers are typically easier to implant and require shorter surgical times while reducing the risk of complications and hospital stays. They are particularly beneficial for patients with specific types of arrhythmia's, such as atrial fibrillation with bradycardia, where pacing is needed primarily in one chambers of the heart.

Implantable pacemakers market from the arrhythmia's application segment is anticipated to witness strong growth over 2024-2032 owing to the high prevalence and increasing diagnosis of various cardiac rhythm disorders, such as atrial fibrillation, bradycardia, and heart block. These conditions disrupt the normal rhythm of the heart, leading to symptoms like fatigue, dizziness, and fainting, for significantly impacting the quality of life of the patients.

Asia Pacific implantable pacemakers industry size is slated to witness decent growth rate during 2024-2032. This is attributed to the rapidly aging population in countries like Japan, China, and South Korea, which is leading to the higher incidence of cardiovascular diseases that require pacemaker intervention. Increasing urbanization and lifestyle changes will also contribute to the rise in heart-related conditions, driving the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of cardiovascular diseases
    • 3.2.1.2 Technological advancements
    • 3.2.1.3 Rising shift towards minimally invasive procedures
    • 3.2.1.4 Favorable reimbursement scenario
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of implantable pacemakers
    • 3.2.2.2 Risks and complications
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Future market trends
• 3.7 Reimbursement scenario
• 3.8 Porter's analysis
• 3.9 PESTEL analysis
• 3.10 Pricing analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Single-chamber pacemakers
  • 5.2.1 Single-chamber atrial
  • 5.2.2 Single-chamber ventricular
• 5.3 Dual-chamber pacemakers
• 5.4 Bi ventricular/CRT pacemakers

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Bradycardia
• 6.3 Arrhythmia
• 6.4 Other applications

Chapter 7 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals & clinics
• 7.3 Cardiac care centers
• 7.4 Ambulatory surgical centers
• 7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories, Inc.
• 9.2 BIOTRONIK SE & Co. KG
• 9.3 Boston Scientific Corporation
• 9.4 Lepu Medical Technology
• 9.5 Medico S.R.L.
• 9.6 Medtronic plc
• 9.7 MicroPort Scientific Corporation
• 9.8 Shree Pacetronix Ltd.
• 9.9 Vitatron